Moberg Pharma AB (FRA:MB8) FFO


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.79
GF Value €1.09
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.

Key valuation signals for FRA:MB8:

  • FFO:
  • GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.09
GF Value